Patents by Inventor David Cameron Pryde

David Cameron Pryde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10538523
    Abstract: The present invention relates to pyrazolopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined in the description. The pyrazolopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They may useful in the treatment of a number of conditions, including pain and epilepsy.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 21, 2020
    Assignee: PFIZER LIMITED
    Inventors: Kevin Neil Dack, Robert McKenzie Owen, David Cameron Pryde
  • Publication number: 20180346470
    Abstract: The present invention relates to pyrazolopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined in the description. The pyrazolopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They may useful in the treatment of a number of conditions, including pain and epilepsy.
    Type: Application
    Filed: November 22, 2016
    Publication date: December 6, 2018
    Applicant: PFIZER LIMITED
    Inventors: KEVIN NEIL DACK, ROBERT MCKENZIE OWEN, DAVID CAMERON PRYDE
  • Patent number: 9802945
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: October 31, 2017
    Assignee: Pfizer Limited
    Inventors: Robert McKenzie Owen, David Cameron Pryde, Mifune Takeuchi, Christine Anne Louise Watson
  • Publication number: 20170197965
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor.
    Type: Application
    Filed: June 3, 2015
    Publication date: July 13, 2017
    Applicant: Pfizer Limited
    Inventors: Robert McKenzie OWEN, David Cameron PRYDE, Mifune TAKEUCHI, Christine Anne Louise WATSON
  • Publication number: 20160355528
    Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Applicant: VIIV HEALTHCARE UK LIMITED
    Inventors: Andrew Simon BELL, Iain Brian GARDNER, Karl Richard GIBSON, David Cameron PRYDE, Florian Michel WAKENHUT
  • Patent number: 9447116
    Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 20, 2016
    Assignee: ViiV Healthcare UK Limited
    Inventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
  • Patent number: 9216229
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: December 22, 2015
    Assignee: Pfizer Vaccines LLC
    Inventors: Alan Daniel Brown, Brian Robert Champion, Clare Lees, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
  • Publication number: 20150259352
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Application
    Filed: May 29, 2015
    Publication date: September 17, 2015
    Inventors: Kiyoyuki Omoto, Robert McKenzie Owen, David Cameron Pryde, Christine Ann Louise Watson, Mifune Takeuchi
  • Publication number: 20150157708
    Abstract: The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.
    Type: Application
    Filed: February 5, 2015
    Publication date: June 11, 2015
    Inventors: Alan Daniel Brown, Heather Lynn Davis, David P. Gervais, Lyn Howard Jones, James R. Merson, David Cameron Pryde, David R. Stead, Michael J. McCluskie, Jennifer Marie Thorn, Paul Robert Mehelic, Parag Ashok Kolhe, Keshab Bhattacharya, Jari Ilmari Finneman, Erin Kristen Parsons, Nickolas Anastasiou
  • Publication number: 20150105396
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Inventors: Kiyoyuki Omoto, Robert McKenzie Owen, David Cameron Pryde, Christine Ann Louise Watson, Mifune Takeuchi
  • Patent number: 8980276
    Abstract: The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: March 17, 2015
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Heather Lynn Davis, David P. Gervais, Lyn Howard Jones, James R. Merson, David Cameron Pryde, David R. Stead, Michael J. McCluskie, Jennifer Marie Thorn, Paul Robert Mehelic, Parag Ashok Kolhe, Keshab Bhattacharya, Jari Ilmari Finneman, Erin Kristen Parsons, Nickolas Anastasiou
  • Patent number: 8952008
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: February 10, 2015
    Assignee: Pfizer Limited
    Inventors: Kiyoyuki Omoto, Robert McKenzie Owen, David Cameron Pryde, Christine Ann Louise Watson, Mifune Takeuchi
  • Publication number: 20140315927
    Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Andrew Simon Bell, lain Brian GARDNER, Karl Richard GIBSON, David Cameron PRYDE, Florian Michel WAKENHUT
  • Patent number: 8809363
    Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: August 19, 2014
    Assignee: VIIV Healthcare UK Limited
    Inventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
  • Publication number: 20140171435
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Application
    Filed: December 12, 2013
    Publication date: June 19, 2014
    Applicant: Pfizer Limited
    Inventors: Kiyoyuki Omoto, Robert McKenzie Owen, David Cameron Pryde, Christine Ann Louise Watson, Mifune Takeuchi
  • Publication number: 20140017239
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Application
    Filed: May 29, 2013
    Publication date: January 16, 2014
    Applicant: PFIZER VACCINES LLC
    Inventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
  • Patent number: 8475801
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: July 2, 2013
    Assignee: Pfizer Vaccines, LCC
    Inventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
  • Publication number: 20120302598
    Abstract: The invention relates to imidazopyridinones, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. By activating TLRs, it should be possible to induce or stimulate immune cells to mount an immune response. In particular, the TLR7 has been implicated in viral infections (such as HCV or HBV), cancers and tumours, and T2 Helper cell (TH2) mediated diseases, and hence TLR7 agonists are potentially useful in the treatment of such diseases. We have now found a series of imidazopyridinones which are agonists of TLR7. According, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is 3- to 8-membered saturated heterocyclic group wherein one ring member is O; and R2 is phenyl or pyridinyl, each optionally substituted by C1-C6alkyl.
    Type: Application
    Filed: November 22, 2011
    Publication date: November 29, 2012
    Applicant: PFIZER LIMITED
    Inventors: Peter H. Jones, David Cameron Pryde, Thien Duc Tran
  • Publication number: 20120294848
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 22, 2012
    Applicant: PFIZER VACCINES LLC
    Inventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
  • Patent number: 8298547
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: October 30, 2012
    Assignee: Pfizer Vaccines, LLC
    Inventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt